Review Article

CFTR activity and mitochondrial function

Angel Gabriel Valdivieso, Tomás A. Santa-Coloma

* Institute for Biomedical Research (BIOMED CONICET-UCA), Laboratory of Cellular and Molecular Biology, School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina
b The National Research Council of Argentina (CONICET), Buenos Aires, Argentina

ABSTRACT

Cystic Fibrosis (CF) is a frequent and lethal autosomal recessive disease, caused by mutations in the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Before the discovery of the CFTR gene, several hypotheses attempted to explain the etiology of this disease, including the possible role of a chloride channel, diverse alterations in mitochondrial functions, the overexpression of the lysosomal enzyme α-glucosidase and a deficiency in the cytosolic enzyme glucose 6-phosphate dehydrogenase. Because of the diverse mitochondrial changes found, some authors proposed that the affected gene should codify for a mitochondrial protein. Later, the CFTR cloning and the demonstration of its chloride channel activity turned the mitochondrial, lysosomal and cytosolic hypotheses obsolete. However, in recent years, using new approaches, several investigators reported similar or new alterations of mitochondrial functions in Cystic Fibrosis, thus rediscovering a possible role of mitochondria in this disease. Here, we review these CFTR-driven mitochondrial defects, including differential gene expression, alterations in oxidative phosphorylation, calcium homeostasis, oxidative stress, apoptosis and innate immune response, which might explain some characteristics of the complex CF phenotype and reveals potential new targets for therapy.

© 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction

Cystic Fibrosis (CF) is one of the most severe and frequent hereditary diseases [1]. It is the main cause of chronic lung damage and exocrine pancreatic insufficiency in the first three decades of life [2]. Other organs and all exocrine glands are also affected to a greater or lesser extent [3].

Lowe and May have described CF as a genetic recessive disorder back in 1949 [4,5]. However, the affected gene was not discovered until 1989, when the team led by Lap-Chee Tsui [6] cloned the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator) and found a deletion of three base pairs in both copies of the gene [6–8]. The deletion causes the loss of a phenylalanine residue at position 508 of the CFTR protein (ΔF508) [6]. Experiments of expression then demonstrated that CFTR was a chloride channel [9–16], as it was suspected for decades [17–32] and intuitively known for many centuries [1,33,34].

Today, more than 1900 mutations have been described for the CFTR gene (Cystic Fibrosis Mutation Database; www.genet.sickkids.on.ca), although the ΔF508 mutation is the most abundant in CF patients, with an occurrence of approximately 66 % [35,36]. It is noteworthy that a clear relationship between genotype and phenotype could not be demonstrated in CF [2]. This is because the different degrees and high variability of the parameters studied in CF reflect the interaction of diverse factors, including genetic and environmental influences, infectious events and differences in treatments [37].

CFTR is an integral membrane glycoprotein frequently located in the apical membrane of the epithelial cells; it is also present in non-apical cells from blood, brain, heart, liver, kidney and other tissues [38–42]. In addition to chloride, the CFTR channel is able to transport bicarbonate [43] and glutathione [44]. On the other hand, the possible role of CFTR as an ATP channel has been controversial [45–54].

The CFTR channel belongs to the superfamily of ABC (ATP Binding Cassette) transporter proteins. The protein includes two nucleotide-binding domains (NBD1 and NBD2) that hydrolyze ATP to regulate the channel activity [55]. In addition, an intracytoplasmic regulatory domain (domain R) is activated by protein kinase A (PKA) phosphorylation to control the opening of the channel [16]. Thus, the chloride transport activity of CFTR is a cyclic AMP-regulated process, a feature that differentiates CFTR from the other chloride channels. The kinases PKC [56] and SRC also regulate the CFTR channel activity [57]. Actually, all molecules or pathways capable of modulating cAMP levels contribute to CFTR activation, including epinephrine, isoproterenol, carbachol, phosphodiesterase inhibitors [58] and G proteins, among other factors [59]. The CFTR protein also forms a macromolecular complex with several proteins, interacting either directly or indirectly [60,61]. Some interactions involve PDZ domain-containing proteins [60,62,63].

Different factors regulate CFTR expression. Cell differentiation in Caco-2 cells induces CFTR up-regulation; the same effect was not observed in T84 cells [64]. In addition, cAMP up-regulates CFTR mRNA levels [65] through a variant cAMP response element (CRE) present at position -48 to -41 of the CFTR promoter [66]. On the other hand, INF-γ [67], TNF-α [67] and progesterone [68] are able to down-modulate CFTR expression. IL-1β modulates CFTR expression of T84 cells in a biphasic way [69]. The CFTR mRNA levels are up-regulated when the cytokine concentration is near 1 ng/ml (≈ 6 FM) and down-modulated at higher concentrations. This biphasic response involves at least two different mechanisms: NF-κB accounts for the stimulation of CFTR mRNA levels at low concentrations of IL-1β (around and below 1 ng/ml) [70] whereas AP-1 is involved in the down-modulation observed at higher concentrations of this cytokine (2–5 ng/ml and higher) [70,71]. Interestingly, IL-1β has been found in sputum from CF children at high concentrations, between 2.8 and 32 ng/ml [72]. At these concentrations, according to the results obtained in T84 cells [69], the CFTR should be strongly down-modulated. Other modulators of CFTR include protein kinase C (PKC), protein tyrosine kinases (PTKs) and phospholipase C (PLC) [69], as well as steroid hormones [73–76], nitric oxide [77–80], hyperosmolarity [81], vasoactive intestinal peptide (VIP) [82,83], c-Src tyrosine kinase (SRC) [57], with-no-lysis [K] 4 kinase (WNK4) [84], casein kinase 2 (CK2) [85] and spleen tyrosine kinase (SYK) [85].

In addition to its CFTR-chloride transport activity, CFTR indirectly regulates the expression of different CFTR-dependent genes, such as SRC and MUC1 [86], MT-ND4 [87], CISD1 [88], RANTES [89], and other genes involved in inflammation or metabolic functions [90–93]. It is noteworthy that two of these genes, MT-ND4 and CISD1, encode for mitochondrial proteins having a reduced gene expression in CF cells [87,88,94–107]. Since ND4 (encoded by mitochondrial MT-ND4) is a key subunit for the activity of mitochondrial Complex I (mtCx-I), the early work of Burton L Shapiro and colleagues [108–113] regarding possible mitochondrial failures in CF was rethought. Subsequent work of our laboratory demonstrated that indeed the activity of mtCx-I was reduced in CF defective cells [87,94,96,97,99]. Later, the mtCx-I failure and other alterations found in the pioneer work of Shapiro and colleagues, including glutathione and calcium metabolism [112–122], were recently confirmed by other laboratories. Here we review the earlier work and the recent findings on CFTR-induced mitochondrial alterations, and their possible pathophysiological consequences.

Initial findings involving mitochondrial alterations in CF

Irena Antonowicz, from the laboratory of Harry Shwachman at Harvard, studied several mitochondrial and lysosomal enzymes in cultures of lymphoid cells obtained from CF patients [123]. They found only alterations in the lysosomal α-glucosidase (which degrades glycogen) without any changes detected in the three mitochondrial enzymes tested: succinate dehydrogenase (succinate-cytochrome Q reductase (SOQ) or respiratory Complex II), glutamate dehydrogenase (GLDH), and malate dehydrogenase (MDH). From these results, the authors concluded that CF might be a lysosomal disorder [123] (unfortunately the authors did not measure NADH dehydrogenase). On the other hand, Congdon and Littlewood found a glucose 6-phosphate dehydrogenase (G6PD) or G6PDH) deficiency in CF [124], although this observation was not further explored.

During the decade before the cloning of CFTR, Shapiro and Feigal reported the existence of different mitochondrial abnormalities in CF [108–113,115,117,125]. First, in 1979, based on previous work from other laboratories [126–130], they found alterations on calcium uptake and oxygen consumption in mitochondria isolated from fibroblasts of CF patients [113]. In the same year, they found alterations in the optimal pH of mitochondrial Complex I (mtCx-I), NADH dehydrogenase, NADH:ubiquinone reductase...
(H+) -translocating), EC 1.6.5.3) and suggested that the mutant gene responsible for CF might be expressed within the mtCx-1 [111]. Later, these same authors found that the increased calcium uptake by mitochondria was associated with an altered respiratory system activity [117] and found a reduced Km of mitochondrial NADH dehydrogenase in whole cell homogenates of cultured skin fibroblasts [110]. After these initial works, several studies described mitochondrial changes in CF [108,109,115,131–133], until the CFTR was cloned and found to be a chloride channel [6,7,134]. Following this important finding, the hypotheses of possible mitochondrial, lysosomal or cytosolic alterations in CF were totally disregarded. Future work mostly focused on the involvement of CFTR as a chloride channel. Few explored other areas. Among them, Picci et al. reported differences in the 2D electrophoretic patterns of mitochondrial proteins in CF [135]. Also, de Meer et al., found higher intracellular pH in CF patients in vivo, during workload [136]. More recently, Day et al. [137] found decreased glutathione levels in epithelial lining fluid of CFTR knockout mice, the last finding also in agreement with the early work of B.L. Shapiro and colleagues, regarding glutathione [119–122]. Now, by using different approaches, several authors are reporting different results in agreement with the pioneer work of Shapiro and colleagues, reinforcing the idea that mitochondrial dysfunctions are indeed present in CF, although as an indirect consequence of CFTR signaling mechanisms, yet undefined.

**Differential expression of genes in Cystic Fibrosis**

Back in 1994, as an approach to explain the diverse phenotypic characteristics of CF, we hypothesized that perhaps the CFTR activity could indirectly affect the expression of several genes. This hypothesis was tested by applying the method of differential display [138]. First, it was necessary to find a way to avoid the frequent false positive/negative signals of this method. Initially, we use T84 colon carcinoma cells treated with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a drug that down-modulates CFTR mRNA levels [139]. Since it was difficult to determine which effects were due to TPA or CFTR, we later changed the model system by using instead CFDE cells (derived from a CF patient) and the same cells ectopically expressing wt-CFTR (CFDE/6RepeCFTR cells). The hypothesis was correct, and we found several CFTR-dependent genes [86,140,141]. Some spots of the differential display corresponded to unknown genes. One spot overexpressed in CFDE cells (CF cells) was studied in detail; its cDNA sequence corresponded to the SRC/c-Src tyrosine kinase. Thus, the mRNA and protein expression of SRC/c-Src was found increased in CFDE cells (CF cells). Since SRC/c-Src was known to regulate several mucins, we tested the expression of MUC1, and found that this mucin was also upregulated in CFDE cells, under SRC/c-Src modulation. These results suggested that SRC/c-Src might constitute a bridge between the CFTR failure and mucin overexpression, at least in the case of MUC1 and CFDE cells [86]. Interestingly, the effects occurred as a primary failure of CFDE cells, in the absence of any bacterial infection.

Almost in parallel, by using microarrays, Srivastava [90,91,93], Galvin [92], Eidelman [142], Pollard [143] and colleagues found several differentially expressed genes in CF cells. In addition, Ichikawa et al. [144] studied the differential expression of genes in the cell line A549, derived from lung pneumocytes, exposed to *Pseudomonas aeruginosa*, thus analyzing differential gene expression in response to bacterial–host interaction. Interestingly, Xu et al. found differential expression of 54 RNAs, corresponding to genes that influence gene transcription, inflammation, intracellular trafficking, signal transduction, and ion transport, including the CEBPβ transcription factor and IL-1β [145,146], both modulators of CFTR transcription [69,70,147]. More recently, Ogilvie et al. have studied the differential expression of genes in CF by using the Illumina HumanRef-8 Expression BeadChips [148]. They conclude that CF and non-CF nasal and bronchial epithelium are transcriptionally distinct. Also, the CF nasal epithelium, with 15 differentially expressed genes, was not a good surrogate for the lung epithelium that has 863 differentially expressed genes. In addition, these cells showed a distinct pattern of enriched pathways, being inflammation pathways predominant in bronchial cells, whereas the pathways controlling amino acid metabolism were predominant in nasal epithelial cells [148]. Lately, antibody microarrays were used instead of DNA micro-arrays to identify differentially expressed proteins as possible serum biomarkers for CF [93,149].

Characterizing SRC/c-Src and MUC1 as CFTR-dependent genes, we decided to study two additional spots of the differential display, which contrary to SRC/c-Src and MUC1 were down-modulated in CFDE cells. Surprisingly, both spots resulted in genes encoding for mitochondrial proteins: CISD1 (a nuclear DNA-encoded gene) [88,98,101,103,105,107,150–152] and MT-ND4 (a mitochondrial DNA-encoded gene) [87,100,102,104,106,141,153–155]. These results are discussed with more detail in the next two sections.

**CISD1 expression in CF cells**

As mentioned above, a differential display (DD) obtained in 2002 from CFDE cells (CF cells) and CFDE/6RepeCFTR (CF corrected cells) showed a cDNA spot that contrary to SRC had a reduced expression in CF cells. It was isolated, cloned and sequenced from a cDNA DD spot of 477 bp derived from CFDE cells. Initially, we called this gene CFTR-RG2 (CFTR-regulated Gene 2), since it was the second CFTR-dependent cDNA isolated and sequenced in our laboratory [150]. Then, in 2004, to assign a name related to its possible function, it was called KLPx, since we found sequence similarities to kinesin motor proteins [107]. Then we realize that the kinesin motor region was absent and therefore we preferred to call it ZCD1, owing to the presence of a Zn finger-like motif, the CDGSH motif [105], defined in a previously annotated sequence obtained by Zhao M. et al. from hematopoietic stem/progenitor cells (AF220049; unpublished). The mRNA corresponding to the ZCD1 sequence from CFDE cells was finally annotated in GenBank as “Homo sapiens zinc finger CDGSH-type domain 1 (ZCD1) mRNA” (accession number AY960578 and AAY32336 for the deduced protein).

Previously, in 1999, Zhao et al. from the Chinese National Human Genome Center at Shanghai had annotated a 636 bp cDNA sequence obtained from hematopoietic stem/progenitor cells as “Homo sapiens uncharacterized hematopoietic stem/progenitor cells protein MDS029” (AF220049, unpublished). They also annotated the deduced protein sequence (AAY32336), defining the region 55.93 as “ZnF_CDGSH” a “CDGSH-type zinc finger”, using the conserved domain database CDD [156]. They also mentioned the SMART signaling domain [157] smart00704, assigning an unknown function to it. Since these results were unpublished and further details are not available, it is not clear who actually defined the CDGSH-type zinc finger, which corresponds today to a superfamily of proteins (CDD cl02748: zf-CDGSH superfamily). In addition, Strausberg et al. [158] annotated the CISD1 sequence as C1orf10r70 (which stand for “chromosome 10 open reading frame 70”) during the generation and analysis of more than 15,000 full-length human cDNA sequences (ORFs) from the human genome, which was sequenced one year before [159].

In parallel, in studies linked to diabetes published in 2003, Colca et al. [161] identified a pioglitazone binding protein from bovine brain and rat liver mitochondria. Pioglitazone, an
antidiabetic drug, also binds to the nuclear peroxisome proliferator-activated receptor gamma (PPAR-γ), which is an important target for antidiabetic drugs [160]. The sequence was obtained by using nanospray LC–mass spectrometry (MS/MS) and N-terminal sequencing confirmed the sequence; it was named mitoNEET [161].

Finally, when the crystal structure was determined by other laboratories [162–164], instead of the predicted Zn2+, a [2Fe–2S] cluster was found within the ZCD1 molecule [162–166]. In consequence, the official HUGO symbol (www.genenames.org) was finally agreed as “CISD1” (Z was eliminated and “IS” was added, which stands for Iron Sulfur binding motif). It is noteworthy that recent evidences suggest that Zn2+ can also bind to CISD1 and even may replace the [2Fe–2S] cluster in E. Coli cultures [167]. In consequence, Zn2+ might also bind to CISD1 in mammalian cells in addition to [2Fe–2S]. A direct measurement of Fe2+ and Zn2+ content of CISD1 isolated from mammalian cells or tissues might indicate in which proportion these ions bind to CISD1 and under which circumstances.

Although the exact function of this protein is unknown yet, it has been shown that mitoNEET/CISD1 is a mitochondrial specific binding protein receptor for pioglitazone [161] and similar drugs [168]. Co-immunoprecipitation assays suggested that mitoNEET/CISD1 was associated with proteins that belong to the mitochondrial complex I (mtCx-I), among other mitochondrial proteins [161]. The protein was also proposed to be a modulator of the oxidative capacity of cells [166], a sensor of the intracellular redox state [164,169,170], and a mediator for the transference of a [2Fe–2S] cluster to apoproteins [169,171]. We found that an eGFP-CISD1 chimera was mainly located in mitochondria after 24 h of transfection, suggesting that its primary location and function was indeed mitochondrial [88]. However, the mechanisms involved in all these possible functions, the targets of these functions, and their relevance for the mitochondrial and cellular functioning, remain to be established. The mechanisms by which CFTR controls CISD1 expression and down-modulation in CF cells [88], and the possible consequences for the cellular pathophysiology, are still unknown.

MT-ND4 expression in CF cells

The second gene found reduced in CF cells, MT-ND4, encodes for ND4, one of the seven subunits (ND1 to ND7) of the mitochondrial Complex I (mtCx-I) [172]. The mammalian mtCx-I is a holoenzyme comprising 45 subunits that constitute a complex of approximately one MDa. This complex is the entry point of electrons for the oxidative phosphorylation system (OXPHOS system) [173]. ND4 subunit constitutes a fundamental component for the assembly and correct activity of mtCx-I [172,174–180]. Thus, a MT-ND4 mutation in Leber’s Hereditary Optic Neuropathy disease (LHON) determines a low efficiency in the NADH oxidation due to a mtCx-I failure [172,179,181]. The reduced expression of MT-ND4 found in CF cells suggested that the activity of mtCx-I might be reduced in CF cells, and, as it will be discussed below, we later found that the activity of these mitochondrial complexes was indeed reduced in CF cells or in cells with impaired CFTR activity (inhibitors, iRNA, etc.).

Mitochondrial complex I and Cystic Fibrosis

As mentioned in the previous section, we found a down-regulation of MT-ND4 in CF, a gene encoding for ND4, a mtCx-I subunit essential for its assembly and activity [100]. The CFTR-mediated down-modulation of MT-ND4 found in CF cells was in agreement with the early findings of Shapiro et al., showing that the activity of mtCx-I was affected in CF cells [108,110,111]. The results obtained and the previous work by other laboratories prompted as to measure the mtCx-I activity in CF cells. Consistent with the earlier observations, we found a decreased mtCx-I activity in cells derived from trachea of CF patients (CFDE and IB3-1 cells) when compared to the same cells ectopically expressing wild type CFTR (wt-CFTR) (CFDE/6RepCFR and S9, respectively) [87,94,97,99]. This was also found in colon carcinoma cells (TB4 and Caco-2), which express high levels of endogenous wt-CFTR, treated either with pharmacological inhibitors of CFTR activity or RNAi [87,94,97,99]. The decreased activity of mtCx-I found in CF cells might be a consequence of the MT-ND4 down-regulation induced by CFTR mutations or inhibition [100]. In agreement with these findings, Kelly-Aubert et al. have recently reported a decrease in mtCx-I activity in CF cells as compared to cells rescued by ectopic expression of wt-CFTR, and also by using a CFTR-knockout mice [182]. These authors suggested that the observed reduction in the specific activity of mtCx-I was caused by oxidation because of the oxidative stress originated in reduced glutathione levels [182]. Altogether, these observations suggest that the mtCx-I activity is altered in CF. The possible mechanisms involved in regulation of mtCx-I by CFTR (CFTR→mtCx-I) are unknown yet.

Altered Ca2+ homeostasis in mitochondria

Recently, Antigny et al. have reviewed the changes occurring in calcium homeostasis and calcium signaling in CF [183]. Donnell et al., back in 1961, were perhaps the first to show alterations of calcium homeostasis in CF [184]. They found evidences of calcium deposition and signs of reparative fibrosis in the bowel of CF patients. Then, Marmar et al. showed altered calcium in parotid gland secretions [185] and Blomfield et al., reported hypersecretion of zymogen granules in the submandibular saliva, with elevated calcium concentrations [186]. Since these initial reports, many investigators found alterations in calcium secretion and homeostasis in CF. Later, Shapiro and Lam [114], based on previous observations from different laboratories [126–130], found increased intracellular calcium concentration ([Ca2+]) in fibroblasts derived from CF patients. Feigal et al. also found an increased mitochondrial Ca2+ uptake attributed to alterations in oxidative phosphorylation [115,117].

More recently, in contrast to the earlier observations of Feigal and Shapiro, Antigny et al. have found a decreased mitochondrial Ca2+ uptake in CF airway epithelial cells (A5F08 homozygous) [187]. The reason for this discrepancy is unknown. In addition, they observed a fragmentation of mitochondria and a decrease of the mitochondrial membrane potential (ΔΨmit) in CF cells as compared to control cells. These changes in mitochondrial Ca2+ homeostasis were linked to a decreased mitochondrial membrane potential (ΔΨmit'), which in turn occurs owing to changes in the oxidative phosphorylation [187].

Among several intracellular pathways activated by calcium, it has been reported that increased [Ca2+]i may lead to activation of NF-κB (“Nuclear Factor Kappa B”) and its proinflammatory effects [188,189]. Thus, the rise in [Ca2+]i observed in CF cells may induce or at least contribute to the increased NF-κB activation seen in these cells. As discussed below, the increased oxidative stress in CF also contribute to activation of NF-κB.

Diverse processes affected in CF and related to mitochondrial pathways

Oxidative stress

Reactive oxygen species (ROS) levels are increased in airway diseases, including CF [182,190–197]. CF cells also show higher
sensitivity to oxidative stress caused by environmental factors, such as ozone [198] and air pollution [199], or infections [200]. The origin and consequences of high ROS levels are not fully understood. Cleeter et al. suggest that a defect in mCx-I may lead to an increased ROS yield, which in turn further affects mCx-I activity [201]. On the other hand, Esposito et al. have shown that inhibition of the OXPHOS system in Ant1tm2Mgr (-/-) mice, lacking the heart/muscle isomer of the adenine nucleotide translocation protein Ant, increases ROS levels. Interestingly, in the same work, as a compensation response, increased levels of manganese superoxide dismutase (Mn-SOD or SOD2) were also observed [202]. They concluded that, if the antioxidant defenses are not enough to deal with high ROS levels, then increased mtDNA damage might occur. Similar results were obtained by Lian and Godley in human RPE cells [203]. The increased mtDNA damage may in turn further reduce the OXPHOS system activity, producing a vicious cycle that results in additional ROS generation [204,205].

**Autophagy**

Autophagy is a natural process by which cells degrade or recycle damaged or unneeded proteins, organelles, and pathogens. The mechanisms of autophagy and their relationship with disease are becoming of high interest [206]. Luciani et al. showed that the CFTR failure in CF induces autophagy inhibition, since defective CFTR upregulates ROS and tissue transglutaminase (TG2), which in turn drive the cross-linking of beclin 1 [195]. This process favors the accumulation of beclin 1 in aggresomes, resulting in a decreased degradation of these juxtanuclear inclusion bodies that appear as a response to misfolded proteins [207]. Rescuing cells from autophagy through beclin 1 overexpression, cysteamine or antioxidants, results in improved CFTR transport and reduced ROS formation and inflammation [195,208]. Abdulrahman et al. observed similar results rescuing autophagy by using the immunosuppressant drug rapamycin on CFTR ΔF508 mouse macrophages [209]. Thus, the excessive intracellular accumulation of defective CFTR observed in CF cells seem to be a consequence of autophagy inhibition and aggresome accumulation [195,208]. Targeting autophagy might be a useful strategy for CF therapy [210].

**Glutathione**

The higher sensitivity to oxidative stress in CF might be associated with several factors that affect the redox balance and the susceptibility to high ROS levels. One of these factors is the ratio between reduced and oxidized glutathione. Reduced glutathione is the most abundant antioxidant inside cells and phospholipid hydroperoxides [220]. Although the mechanism responsible for decreased Prdx6 expression in CF is unknown, these results are in agreement with the general idea of a redox imbalance and higher susceptibility to oxidative damage in CF.

**Possible pathophysiological consequences**

**Apoptosis**

Except for one work [224], different investigators have found increased apoptosis in CF [191,192,198,199,225–228]. Although several studies suggest that apoptosis in CF is a consequence of the recurrent bacterial infections [225,226,228], others suggest that apoptosis in CF is a primary defect that occurs even in the absence of bacterial infections [191,192,227,229]. In infected human conjunctival epithelial Chang cells, apoptosis mediated by mitochondrial alterations was induced after infection with P. aeruginosa. These alterations include mitochondrial depolarization, enhanced ROS production, release of cytochrome c, and activation of c-Jun N-terminal kinases (JNKs) [200]. On the other hand, in JME cells (CF ΔF508CFFT nasal epithelial cells), the homoserine lactone C12 rapidly activates apoptosis. However, no differences were seen between JME cells and CFTR corrected JME cells after C12 treatment, suggesting that CFTR is not an important modulator of C12-induced apoptosis [228]. It should be pointed-out, however, that corrected JME cells ectopically express wt-CFTR under the control of a foreign promoter, thus possible feedbacks on its own promoter are missing.

**Superoxide Dismutases (SODs)**

Another factor that affects the redox balance is the level and activity of superoxide dismutases (SOD, EC 1.15.1.1). SOD enzymes are key components of the cellular defense system against the production of the free radical superoxide (O2−), by dismutation of O2− in oxygen (O2) and hydrogen peroxide (H2O2). A decreased protein expression of Cu/Zn-SOD (SOD1, cytosolic localization) and Mn-SOD (SOD2, mitochondrial localization) was found in pancreatic and tracheal cells derived from CF patients, without changes in their activities [192]. By the contrary, a decrease in the activity of extracellular SOD (EC-SOD/SOD3) was observed in CF cells, without changes in its protein expression level [192]. These results are in agreement with previous work in which a decrease in the SOD activities was found in plasma of CF patients [221]. They are also in agreement with a decrease in the Cu/Zn-SOD activity of blood cells (mononuclear cells and polymorphonuclear cells) from CF patients [222,223]. The diminished extracellular SOD activity, together with the diminished eGSH, could produce a misbalance in the extracellular redox state, affecting the structure and function of many membrane and extracellular proteins.
Other studies suggest that the increased apoptosis in CF might be related to a decrease in the antioxidant protection system, which may contribute to self-perpetuate the inflammatory process characteristic of CF [191,192,199]. In particular, Rottner et al. reported a marked sensitivity of CF cells to start apoptosis linked to activation of the NF-κB pathway, suggesting that the secretion of proinflammatory cytokines from these cells promote apoptosis [227]. Recently, a link between the high level of the oxidative stress and apoptosis has been attributed to a decrease in the antioxidant defenses, caused by reduced activity and expression of superoxide dismutase (SOD) enzymes [192]. Hence, a tendency to increased apoptosis mediated by the mitochondrial pathway seems to occur in CF cells, probably exacerbated upon bacterial infections.

**Chronic inflammation**

Chronic lung inflammation is an important characteristic of the CF phenotype [230,231]. Yet, it is difficult to define and distinguish primary defects due to the CFTR failure from secondary defects that occur after bacterial infections. It is even more difficult to determine their relative weight in defining the CF phenotype or its clinical manifestations.

In early studies, several cytokines were found to be elevated in sputum obtained from CF patients, including IRAP, IL-1α, IL-1β, IL-6, and TNF-α [232,233]. In addition, in neutrophils from CF patients, IL-8 was found at high levels and its receptors down-modulated [234]. After these initial studies, several reports suggest elevated concentrations of cytokines, chemokines (small cytokines) and other inflammatory mediators in CF patients [72,235–250]. The role of Interleukin-1, neutrophil elastase and lipopolysaccharide to regulate inflammation in CF has been reviewed by Carroll et al. [251].

Studying possible modulators of CFTR expression, we found that IL-1β was able to modulate CFTR expression in a biphasic way. At low concentrations (< 1 ng/ml) IL-1β up-regulates CFTR mRNA levels [69] through NF-κB [70,71]. However, at concentrations over 2.5 ng/ml (between 2.3 and 32 ng/ml were found in CF children [72]), the IL1-β effect was the contrary, inducing a down-regulation of CFTR expression. The mechanism involved in this second phase was not fully defined yet and might involve the AP-1 transcription factor [71], as occurs with TNF-α, which down-modulates CFTR mRNA by increasing its degradation through the AP1 pathway [252–255]. These results suggest that CF children, having high concentrations of IL-1β and TNF-α, should have a strong down-modulation of CFTR, which together with the low levels of ΔF508-CFTR able to reach the cell membranes in CF cells, might constitute a negative loop with profound consequences for the disease. In addition, CFTR negatively regulates NF-κB-mediated innate immune response [256], establishing an additional loop between CFTR and NF-κB (CFTR–NF-κB → CFTR). In addition to its effects on CFTR, IL-1β reduces the mtCx-I activity in human chondrocyte cells [257] and its mRNA was found elevated in cells with impaired CFTR activity [95,258,259]. Therefore, IL-1β might be an important piece of the CFTR → mitochondrial signaling.

Following these initial studies, additional cytokines were found increased in CF, including IL-8 [259–265] and IL-17 [266–270]. The increased concentrations of different cytokines might be responsible for the abundant neutrophil recruitment observed in CF and drive the activation of transcription factors such as the nuclear factor-κB (NF-κB) [271,272] and the activator protein 1 (AP-1) [273], increasing in turn the inflammatory response with the consequent tissue damage. Now, numerous studies support the concept that alterations in the inflammatory process are present in CF [247,264,274–278].

**Innate immunity**

A central question is whether the mitochondrial defects found in CF are strong enough to influence innate immunity and, in the long-term, favor lung bacterial infections. Initial works in models of viral infection connected mitochondria, apoptosis and innate

---

**Fig. 1.** Representative scheme for mitochondrial alterations in CF. The effects of a CFTR failure on ROS production, apoptosis and inflammation are shown, together with the main relationships between mitochondrial activity and antioxidant defense system in CF. CFTR inhibition or mutation leads to mitochondrial alterations that produce an imbalance in the antioxidant defense system and an impairment of the OXPHOS system, inducing an excessive ROS production by mitochondria. The nosious effects of ROS include DNA, protein and lipids damage, apoptosis and inflammation, the latter due to ROS-induced NF-κB. Also, the CFTR failure induces an alteration in calcium homeostasis for the mitochondria. All these effects suggest an important role of the mitochondria in defining at least some of the phenotypic characteristics of CF. The vertical black arrows indicate the net effect of a CFTR failure. The red connectors illustrate positive interactions and the black ones (→) inhibition. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
immunity [279–282]. Then, death receptors (DRs) have been recognized as modulators of immune and inflammatory responses [283]. Also, it has been shown that exacerbated inflammation might impair the function and structure of mitochondria [284]. More recently, studies on pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and cytosolic Nod-like receptors (NLRs), have become important players in the innate immune and inflammatory responses [285,286]. These studies led to the characterization of the “inflammasome”, a macromolecular complex that uses NLRs as scaffold proteins, which recruits and activates inflammatory caspases, essential mediators of inflammation and cell death responses. The activation of caspases directly connects to the mitochondrial apoptotic pathways [287]. Mitochondria, in turn, play a very important role in modulation of the cell death pathway during defense against bacterial infections [287]. In addition, the process of autophagy [288–290] and the production of ROS [291,292] became new players in defining innate immunity. Even more, mitochondria by itself, once released from damaged cells, can trigger an acute inflammatory response [293]. Thus, mitochondria emerges as a fundamental piece of the innate immune response [294–297], modulating the inflammasome-mediated production of proinflammatory cytokines [298]. Dysfunctional mitochondria generate ROS and induce the NLRP3 inflammasome activation [299,300]. On the other hand, autophagy negatively regulates the NLRP3 inflammasome [299]. In consequence, the role of autophagy [195,208,209,301–305] and the inflammasome [303,306,307] both have increased relevance in CF research.

Concluding remarks

Fig. 1 summarizes the mitochondrial abnormalities found in CF cells or tissues. Among them, differential expression of genes or proteins, alterations on calcium homeostasis, membrane potential, increased ROS, and reduced Complex I activity, all appear to occur in mitochondria due to the CFTR failure. These mitochondrial effects in turn induce changes in the ratio of reduced/oxidized glutathione, trigger apoptotic events, and produce inflammatory responses that affect innate immunity. These alterations might influence the phenotype or clinical manifestations of CF and have profound pathophysiological consequences. A complete understanding of these interactions, their mechanisms of action and the relative importance of each pathway, will help to better define the CF phenotype and clinical manifestations, and to find possible new targets for CF therapy. Thus, the role of CFTR in regulating mitochondrial functions, in particular de OXPHOS pathway, and the role of mitochondria in modulating the inflammatory process, and their possible effects on innate immunity, are issues of increasing interest in CF research.

Acknowledgments

This work was supported by the National Agency for the Promotion of Science and Technology (ANPCYT, grant PICT 2007–00628 to TASC) and the National Research Council of Argentina (CONICET, grant PIP 11220080 102551, 2009–2011 to TASC) and research fellowships from CONICET to AGV, and Pontificial Catholic University of Argentina (grant to TASC and fellowships to AGV).

References

[1] P.M. Quinton, Cystic fibrosis: lessons from the sweat gland, Physiology (Bethesda) 22 (2007) 212–225.

[2] J. Zielenksi, Genotype and phenotype in cystic fibrosis, Respiration 67 (2000) 117–133.

[3] H. Heijerman, Infection and inflammation in cystic fibrosis: a short review, Journal of Cystic Fibrosis 4 (Suppl. 2) (2005) S–5.

[4] C.D. Lowe, C.D. May, S.C. Reed, Fibrosis of the pancreas in infants and children: a statistical study of clinical and hereditary features, American Journal of Diseases of the Chest 88 (1949) 349–374.

[5] C.D. May, C.D. Lowe, Fibrosis of the pancreas in infants and children: an illustrated review of certain clinical features with special emphasis on the cystic fibrosis gene, Philosophical Transactions of the ROYAL Society of London Series B, Biological Sciences 319 (1988) 263–273.

[6] J.M. Rommens, M.C. Iannuzzi, B. Kerem, J. Loeve, H. Petit, M. Schaal, P. Topalov, M. Vainchenker, C. White, A. Zeviani, W.J. Warren, E. Westenfeld, Cystic fibrosis mutations, Science 235 (1987) 1531–1535.

[7] L.C. Tsui, J.M. Rommens, J. Burns, M. Kerem, C. Marazita, J.R. Riordan, P. Schinzel, J.R. Zielenski, S. Zengerling, J.R. Riordan, L.R. Carver, J.R. Riordan, Localization of the cystic fibrosis gene to chromosome 7, Science 245 (1989) 1059–1065.

[8] S.M. Shwachman, J.H. Widdicombe, Altered chloride transport of tracheal epithelium in cystic fibrosis, Nature 264 (1976) 729–730.

[9] L. Ostedgaard, K.W. Klinger, M.J. Welsh, A.E. Smith, Characterization of the cystic fibrosis transmembrane conductance regulator, Nature 347 (1990) 382–386.

[10] M.D. Jefferson, J.D. Valentich, V.C. Marini, D.A. Grubman, M.C. Iannuzzi, C. Rich, L. Ostedgaard, K.W. Klinger, M.J. Welsh, Expression and characterization of the cystic fibrosis transmembrane conductance regulator, Nature 347 (1990) 382–386.

[11] D.M. Jefferson, J.D. Valentich, M.C. Iannuzzi, C. Rich, F.M. Anderson, J.R. Gregson, S. Cheng, A. Keszler, E. Ackerman, C. Weidenfield, R.A. Gambini, B. Kerem, J.R. Riordan, Characterization of the cystic fibrosis transmembrane conductance regulator, Nature 347 (1990) 382–386.

[12] D.P. Rich, M.P. Anderson, R.J. Gregson, S.H. Cheng, S. Paul, R.C. Mulligan, A.E. Smith, M.J. Welsh, Demonstration that CFTR is a chloride channel by alteration of its anion selectivity, Science 253 (1990) 202–205.

[13] M.P. Anderson, D.P. Rich, J.R. Gregson, A.E. Smith, M.J. Welsh, Generation of CFTR inhibited chloride currents by expression of CFTR, Science 251 (1991) 679–682.

[14] C.E. Bear, P. Duguy, A.L. Naismith, N. Kartner, J.W. Hanrahan, J.R. Riordan, Cl– channel activity in Xenopus oocytes expressing the cystic fibrosis gene, Journal of Biological Chemistry 266 (1991) 19142–19145.

[15] D.N. Sheppard, M.J. Welsh, Structure and function of the CFTR chloride channel, Physiological Reviews 79 (1999) 523–545.

[16] N. Gahm, H. Shwachman, Studies in cystic fibrosis of the pancreas; a simple test for the detection of excessive chloride on the skin, New England Journal of Medicine 255 (1956) 999–1001.

[17] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[18] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[19] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[20] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[21] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[22] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[23] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[24] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.

[25] G.J. Barbero, M.S. Sibning, The electrolyte abnormality in cystic fibrosis, Pediatric Clinics of North America 11 (1964) 983–1001.
E.A. Pasyk, J.K. Foskett, Cystic fibrosis transmembrane conductance regulator-associated ATP and adenosine 3'5'-phosphosulfate channel, J. Biol. Chem. 267 (1992) H2214–2220.

E. Horowitz, S.S. Tsung, P. Hart, P.C. Levesque, J.R. Hume, Alternative splicing of CFTR channels in heart, Circulation Research 71 (1992) 1002–1007.

E. F. Tizzano, D. Chitayat, M. Buchwald, Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues, Human Molecular Genetics 2 (1993) 219–224.

H.C. Chan, Q.X. Shi, C.X. Zhou, X.F. Wang, W.M. Xu, W.Y. Chen, A.J. Chen, Y. Ni, Y.Y. Yuan, Critical role of CFTR in uterine bicarbonate secretion and the fertilizing capacity of sperm, Molecular and Cellular Endocrinology 250 (2006) 106–113.

E. Osika, J.M. Cavaillon, K. Chadelat, M. Boule, C. Fitting, G. Tournier, E.G.A. Cafferata, Regulación del gen CFTR (affectado en fibrosis quística) en células de carcinoma de colon humano T84, Thesis dissertation of Pharmacy and Biochemistry, University of Buenos Aires (2002) 1–106.

E. F. Tizzano, D. Chitayat, M. Buchwald, Down-regulation by progestrone of CFTR expression in endometrial epithelial cells: a study by competitive RT-PCR, Biochemical and Biophysical Research Communications 217 (1995) 1105–1111.

E.G. Cafferata, A.M. Gonzalez-Guerrico, O.H. Pivetta, T.A. Santa-Coloma, NF-κB activation is involved in regulation of cystic fibrosis transmembrane conductance regulator (CFTR) by interleukin-1β, Journal of Biological Chemistry 276 (2001) 15441–15444.

E.G. Cafferata, R. Abrahams, Expresión del gen CFTR (afectado en fibrosis quística) en células de carcinoma de colon humano T84, Thesis dissertation of Pharmacy and Biochemistry, University of Buenos Aires (2002) 1–106.

J. Texereau, S. Marullo, D. Hubert, J. Coste, D.J. Dusser, J. Dall'Ava-Santucci, S. Marullo, D. Hubert, J. Coste, D.J. Dusser, J. Dall'Ava-Santucci, P. Okunieff, Erythrocyte membrane conductance regulator as well as a chloride channel, Physiological Reviews 75 (1995) 115–180.

E.G. Cafferata, A.M. Gonzalez-Guerrico, O.M. Pivetta, T.A. Santa-Coloma, NF-κB activation is involved in regulation of cystic fibrosis transmembrane conductance regulator (CFTR) by interleukin-1β, Journal of Biological Chemistry 276 (2001) 15441–15444.

J. H. Thakar, A. Lorico, G. Rappa, A.C. Sartorelli, P. Okunieff, Erythrocyte membrane conductance regulator-associated ATP and adenine 3'-phosphate 5'-phosphosulfate channels in endothelial reticulum and plasma membranes, Journal of Biological Chemistry 272 (1997) 7746–7751.

H.F. Cantiello, C.G. Jackson Jr., C.R. Grosman, A.G. Pratt, S.C. Borkan, Y. Wang, L.L. Reisen, C.R. O' Riordan, D.A. Ausiello, Cellular ATP release by the cystic fibrosis transmembrane conductance regulator, American Journal of Physiology 270 (1996) C535–48.

H.F. Cantiello, Nucleotide transport through the cystic fibrosis transmembrane conductance regulator, Bioscience Reports 17 (1997) 147–171.

S. Devidas, W.B. Chung, T. Hagg, The cystic fibrosis transmembrane conductance regulator and ATP, Current Opinion in Cell Biology 9 (1997) 547–552.

E.A. Pasyk, J.K. Foskett, Cystic fibrosis transmembrane conductance regulator-associated ATP and adenine 3-phosphate 5-phosphosulfate channels in endolysosomal reticulum and plasma membranes, Journal of Biological Chemistry 272 (1997) 7746–7751.

H.F. Cantiello, C.G. Jackson Jr., C.R. Grosman, A.G. Pratt, S.C. Borkan, Y. Wang, L.L. Reisen, C.R. O’ Riordan, D.A. Ausiello, ATP Electrodifusional, movement through the cystic fibrosis transmembrane conductance regulator, American journal of physiology 274 (1998) C799–809.

E.H. Abraham, K.M. Sterling, R.J. Kim, A.Y. Salikhova, H.B. Huffman, M.A. Cockett, N. Johnson, H.W. Parker, W.E. Boyle Jr., A. Hartov, E. Sciaky, J.K. Kahn, S.A. Graubart, J.H. Thakar, A. Lorico, G. Rappa, A.C. Sartorelli, P. Okunieff, Erythrocyte membrane ATP binding cassette (ABC) proteins: MRPI and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis in blood donors, Biochemical and Molecular Biology 27 (2001) 165–180.

H.F. Cantiello, ATP Electrodifusional, movement through CFTR and other ATP transporters, Archives 44 (2001) 111–127.

D. Regada, C.H. Mitchell, Release of ATP from retinal pigment epithelial cells involves both CFTR and vesicular transport, American journal of Physiology Cell Physiology 285 (2003) C132–140.

J.H. Chen, H. Schultman, P. Gardiner, A CAMP-regulated chloride channel in human cells affected by cystic fibrosis, Science 243 (1989) 657–660.

C.A. Boyd, Function of cystic fibrosis gene product, Lancet 336 (1990) 938.

R. Busch, On the history of cystic fibrosis, Nordisk Medicinhistorisk Arsbok 18 (1995) 91–98.

P.M. Quinones, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.

E. Kerem, M. Corey, B.S. Kerem, J. Rommens, D. Markiewicz, H. Levison, P.M. Quinton, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.

R.C. Boucher, C.U. Cotton, J.T. Gatzy, M.R. Knowles, J.R. Yankaskas, Evidence for reduced Cl– channel activity in sweat of cystic fibrosis patients, Science 243 (1989) 657–660.

E. Kerem, M. Corey, B.S. Kerem, J. Rommens, D. Markiewicz, H. Levison, P.M. Quinton, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.

R. Busch, On the history of cystic fibrosis, Nordisk Medicinhistorisk Arsbok 18 (1995) 91–98.

P.M. Quinones, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.

E. Kerem, M. Corey, B.S. Kerem, J. Rommens, D. Markiewicz, H. Levison, P.M. Quinton, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.

R. Busch, On the history of cystic fibrosis, Nordisk Medicinhistorisk Arsbok 18 (1995) 91–98.

P.M. Quinones, Physiological basis of cystic fibrosis: a historical perspective, Physiological Reviews 79 (1999) 53–522.
G.L. Taminelli, A.G. Valdivieso, T.A. Santa-Coloma, Abstract 625. Expresión de mitocondrial denominada CISD1. Abstracts of the 52th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 21–24 November 2007, Medicina (Buenos Aires) 67 (Suppl. III) (2007) 241.

A.G. Valdivieso, G.L. Taminelli, M.L. Teiber, M.A. Dankert, T.A. Santa-Coloma, Abstract CB-P82. Down-regulation of the mitochondrial gene ND4 in Cystic Fibrosis. Abstracts of the 42th annual meeting of the Argentine society for biochemistry and molecular biology research. Rosario, Argentina; 12–15 November 2006, Abstract Book 81 (2006).

G.L. Taminelli, A.G. Valdivieso, F. Marcucci, G.L. Taminelli, M.C. Marín, M.L. Teiber, M.A. Dankert, T.A. Santa-Coloma, Abstract CB-P81. ZC1D is a new mitochondrial-localized protein down-regulated in cystic fibrosis. Abstracts of the 42th annual meeting of the Argentine society for biochemistry and molecular biology research. Rosario, Argentina; 12–15 November 2006, Abstracts Book 81 (2006).

G.L. Taminelli, A.G. Valdivieso, C.F.C. Tironi Farinati, G.B. Reyes, V. Calabró, M.A. Dankert, T.A. Santa-Coloma, Abstract 451. Regulación del gen ND4 mitocondrial mediada por el canal de cloruro CFTR. Abstracts of the 50th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 29 November – 2 December 2005, Medicina (Buenos Aires) 65 (Suppl. II) (2005) 167.

G.L. Taminelli, A.G. Valdivieso, M.C. Marín, A.C.F. Tironi Farinati, V. Calabró, M.A. Dankert, T.A. Santa-Coloma, Abstract 449. Caracterización de ZC1D, un gen nuclear de localización mitocondrial disminuido en Fibrosis Quística. Abstracts of the 50th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 29 November – 2 December 2005, Medicina (Buenos Aires) 65 (Suppl. II) (2005) 166.

A.G. Valdivieso, F. Marcucci, G.L. Taminelli, G.B. Reyes, V. Calabró, M.A. Dankert, T.A. Santa-Coloma, Abstract 308. El canal de cloruro CFTR, afectado en Fibrosis Quística, es un componente esencial del Complejo I mitocondrial que es clave para el transporte de electrones. Abstracts of the 49th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 16–20 November 2004, Medicina (Buenos Aires) 64 (Suppl. II) (2004) 163.

G.L. Taminelli, V. Sotomayor, A.G. Valdivieso, G.B. Reyes, M.A. Dankert, T.A. Santa-Coloma, Abstract 309. KFLX es una proteína de localización mitocondrial con un dominio “Zn finger” similar al de algunas kinetas y cuya expresión está disminuida en Fibrosis Quística. Abstracts of the 49th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 16–20 November 2004, Medicina (Buenos Aires) 64 (Suppl. II) (2004) 163.

B.L. Shapiro, Evidence for a mitochondrial lesion in cystic fibrosis, Life Sciences 44 (1989) 1327–1334.

B.L. Shapiro, Mitochondrial dysfunction, energy expenditure, and cystic fibrosis, Lancet 2 (1988) 289.

B.L. Shapiro, L.F. Lam, R.J. Feigal, Mitochondrial NADH dehydrogenase in cystic fibrosis: enzyme kinetics in cultured fibroblasts, American Journal of Human Genetics 34 (1982) 846–852.

B.L. Shapiro, R.J. Feigal, L.F. Lam, Mitochondrial NADH dehydrogenase in cystic fibrosis, Proceedings of the National Academy of Sciences of the United States of America 76 (1979) 2979–2983.

R.J. Feigal, B.L. Shapiro, Altered intracellular calcium in fibroblasts from patients with cystic fibrosis and heterozygotes, Pediatric Research 13 (1979) 764–768.

R.J. Feigal, B.L. Shapiro, Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis, Nature 278 (1979) 276–277.

B.L. Shapiro, L.F. Lam, Intracellular calcium in cystic fibrosis heterozygotes, Life Sciences 43 (1988) 921–928.

R.J. Feigal, B.L. Shapiro, Cystic fibrosis—a lethal enocrinopathy with altered mitochondrial calcium metabolism, Annals of the New York Academy of Sciences 488 (1986) 82–98.

B.L. Shapiro, L.F. Lam, Calcium and age in fibroblasts from control subjects and patients with cystic fibrosis, Science 216 (1982) 417–419.

R.J. Feigal, M.S. Tomczyk, B.L. Shapiro, The calcium abnormality in cystic fibrosis mitochondria: relative role of respiration and ATP hydrolysis, Life Sciences 30 (1982) 93–98.

B.L. Shapiro, R.J. Feigal, N.J. Laible, M.H. Biros, W.J. Warwick, Doubling time and alpha-aminobutyrate transport and calcium exchange in cultured fibroblasts from cystic fibrosis and control subjects, Clinica Chimica Acta 82 (1978) 123–131.

B.L. Shapiro, R.J. Feigal, N.J. Laible, M.H. Biros, W.J. Warwick, Double time alpha-aminobutyrate transport and calcium exchange in cultured fibroblasts from cystic fibrosis and control subjects, Clinica Chimica Acta 82 (1978) 123–131.

B.L. Shapiro, Q.T. Smith, W.J. Warwick, Letter: serum glutathione reductase and cystic fibrosis, Pediatric Research 10 (1976) 250.

B.L. Shapiro, Q.R. Smith, W.J. Warwick, Serum glutathione reductase and cystic fibrosis, Pediatric Research 9 (1975) 888–888.

B.L. Shapiro, Q.T. Smith, A. Martinez, Letter: white-cell glutathione reductase in cystic fibrosis, Lancet 2 (1974) 1020–1021.

B.L. Shapiro, Q.T. Smith, R.J. Feigal, Red cell glutathione and glutathione reductase in cystic fibrosis, Proceedings of the Society for Experimental Biology and Medicine 144 (1973) 181–183.

I. Antonowicz, W.G. Sippell, H. Shwachman, Cystic fibrosis: lysosomal and mitochondrial enzyme activities of lymphoid cell lines, Pediatric Research 10 (1976) 803–812.

P.J. Condon, J.M. Littlewood, R.K. Aggarwal, H. Shapiro, Glucose 6-phosphate dehydrogenase deficiency and cystic fibrosis, Postgraduate Medical Journal 57 (1981) 46–50.

B.L. Shapiro, L.F. Lam, L.H. Fast, Premature senescence in cultured skin fibroblasts from subjects with cystic fibrosis, Science 203 (1979) 1251–1253.
Cystic fibrosis: mitochondrial abnormalities suggest a modification of the mitochondrial membrane, Pediatric Research 18 (1984) 594–599.

R.L. Waller, W.J. Brattin, D.G. Dearborn, Cytosolic free calcium concentration and intracellular calcium distribution in lymphocytes from cystic fibrosis patients, Life Sciences 35 (1984) 775–781.

M.C. Dehecchi, E. Girella, G. Cabrini, G. Berton, The Km of NADH dehydrogenase is decreased in mitochondria of cystic fibrosis cells, Enzyme 40 (1988) 45–50.

J.M. Rommens, S. Wotman, I.D. Mandel, J. Mercadante, C.R. Denning, Parotid and submaxillary calcium metabolism and cystic fibrosis, Thorax 50 (1995) 980–983.

S. Fidel, F. Marcucci, Identificación de genes regulados por CFTR, canal de cloruro afectado en Fibrosis Quística (FQ). Abstracts of the 48th annual meeting of the Argentine society for biochemistry and molecular biology research. Villa Giardino, Córdoba, Argentina; 13-18 November 1995, Abstracts Book (1995).

A. Marchler-Bauer, A.R. Panchenko, B.A. Shoemaker, P.A. Thiessen, L.Y. Geer, Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery, Annual Review of Pharmacology and Toxicology 51 (2001) 497–525.

M.L. Rosenlund, Tear sodium, potassium, chloride and calcium at various flow rates: children with cystic fibrosis and non-cystic fibrosis subjects with and without concomitant Staining. Journal of Pediatrics 83 (1973) 601–606.

H.M. Allars, J. Blomfield, A.R. Rush, J.M. Brown, Colloid and crystal formation in parotid saliva of cystic fibrosis patients and non-cystic fibrosis subjects. J. Laryngol. Otol. 104 (1990) 574–584.

J. Blomfield, A.R. Rush, H.M. Allars, J.M. Brown, Parotid gland function in children with cystic fibrosis and child control subjects, Pediatric Research 17 (1983) 574–579.

A.A. von Ruecker, R. Bertele, H.K. Harms, Calcium metabolism and cystic fibrosis: mitochondrial abnormalities suggest a modification of the mitochondrial membrane, Pediatric Research 18 (1984) 594–599.

T.A. Santa-Coloma, E. Cafferata, A.M. González-Guerrico, O.H. Pivetta, T.A. Santa-Coloma, Abstracts of the 31st annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 20–23 November 2002, Medicina (Buenos Aires) 62 (5) (2002) 457.

F. Marcucci, V. Sotomayor, B. Reyes, T.A. Santa-Coloma, Abstract 282. Identificación mediante diseño diferencial de N4D como gen dependiente de CFTR. Cystic fibrosis abstracto en fibrosis quística. Abstracts of the 47th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 20–23 November 2002, Medicina (Buenos Aires) 62 (5) (2002) 457.

F. Marcucci, V. Sotomayor, B. Reyes, T.A. Santa-Coloma, Abstract 282. Identificación mediante diseño diferencial de N4D como gen dependiente de CFTR. Cystic fibrosis abstracto en fibrosis quística. Abstracts of the 47th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 20–23 November 2002, Medicina (Buenos Aires) 62 (5) (2002) 457.

R.L. Waller, W.J. Brattin, D.G. Dearborn, Cytosolic free calcium concentration and intracellular calcium distribution in lymphocytes from cystic fibrosis patients, Life Sciences 35 (1984) 775–781.

S. Wotman, I.D. Mandel, J. Mercadante, C.R. Denning, Parotid and submaxillary calcium metabolism and cystic fibrosis, Thorax 50 (1995) 980–983.

R.J. Ichikawa, A. Norris, M.G. Bangera, G.K. Geiss, A.B. van’t Wout, A.G. Valdivieso, T.A. Santa-Coloma / Redox Biology 1 (2013) 190–202

E. G. Valdivieso, T.A. Santa-Coloma / Redox Biology 1 (2013) 190–202

V. Sotomayor, F. Marcucci, T.A. Santa-Coloma, Abstract 445. Identificación de genes regulados por la actividad del CFTR, canal de cloruro afectado en la fibrosis quística (FQ). Abstracts of the 47th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 20–23 November 2002, Medicina (Buenos Aires) 62 (5) (2002) 457.

V. Sotomayor, F. Marcucci, T.A. Santa-Coloma, Abstracts of the 47th annual meeting of the Argentine society for clinical investigation. Mar del Plata, Buenos Aires, Argentina; 20–23 November 2002, Medicina (Buenos Aires) 62 (5) (2002) 457.
C. Derosa, F. Scialdone, Peroxisome proliferator-activated receptor-gamma
2 subunit of complex I induces optic neuropathy in the mouse, Investigative
Sciences of the United States of America 108 (32) (2011) 13047–13052.
N. Antigny, N. Girardin, D. Raveau, M. Frieden, F. Becq, C. Vandebrouck,
diabetes drug target MitoNEET to an apo-acceptor protein, Journal of
P. M. Cleeter, J. M. Cooper, A. H. Schapira, Irreversible inhibition of mito-
M. Iuliano, M. Piroddi, M. C. Dechecchi, G. Cabrini, Oxidative stress and
C. I. Snow, J. C. C. S. Lin, J. E. Dixon, P. A. Jennings, MitoNEET
in human cystic fibrosis cells, PLoS One 6 (2011) e24880.
R. C. Boucher, Cystic fibrosis models, Human Molecular Genetics 20 (2011)
F. Brouillard, A. Edelman, GSH monoethyl ester rescues mitochondrial
etinopathy (LHON), FEBS Letters 292 (1991) 289–292.
E. F. Liang, B. F. Godley, Oxidative stress-induced mitochondrial DNA damage
4820–4825.
A. Luciani, V. R. Villella, S. Esposti, N. Brunetti-Pierri, D. Medina,
M. D’aPpolito, S. Guido, E. Masliah, B. Spencer, S. Quaratino, V. Raia,
F. Omura, G. Osawa, K. Shewry, J. R. James, H. Sato, G. M. Bohr,
G. P. Hogg, C. F. T. Widmann, M. D’Apollito, S. Guido, E. Masliah,
C. Settembre, M. Gavina, L. Pulze, I. Giardino, M. Pettoello-Mantovani,
V. E. Khot, A. Chargui, R. Belfidi, E. Corcelle, C. Duranton, I. Rubera,
S. L’Hoste, A. Chargui, R. Belfidi, C. Durand, I. Rubera, C. Poujol,
M. G. D. Rosen, J. B. Flower, M. J. Pitzikas, M. A. Carew, S. J. Dowling,
I. G. MacRae, A. I. Oates, L. Y. Yu, D. L. Prior, M. T. Stone, C. A. Friend,
E. Masliah, C. Cambon, and A. R. Johnson, Oxidative stress and
effects prove that mitochondrial DNA repair is inversely correlated with
D. Tsuda, T. Matsuda, M. Araki, J. Yamauchi, S. S. Taylor, M. Nakamura,
C. Marcinkowski, H. Murayama, M. R. D. Hunt, D. J. Martin, J. A. Rock, D.
L. Suchowerska, M. V., M. Barbet, G. D. P. Carvalho, J. de Carvalho,
Y. Zhang, X. Li, H. Grassme, G. Doring, E. Ulbinski, Alterations in ceramide
infection in cultured mice proximal tubules, American Journal of Physiology—R-
enzetti, W. Thiery, J. Thiery, M. Levec, M. Triantafyllou, G. A. Torchiano,
M. D’Apollito, I. Guiducci, A. R. Johnson, M. J. Pitzikas, M. A. Carew,
J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis,
M. Garcia, J. H. Williams, R. L. Cobb, J. A. Gallegos, C. J. Lin, T. Zhou, K.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. tendência is the new born associated
complex I in mammalian cells, Journal of Molecular Graphics and Modelling 22
in Chlamydomonas. Implication for the structural organization of the
C. A. Friend, D. L. Prior, M. T. Stone, C. A. Friend, J. C. Maher, M. J. Pitzikas,
F. Brouillard, A. Edelman, GSH monoethyl ester rescues mitochondrial
drug target MitoNEET to an apo-acceptor protein, Journal of
C. Settembre, M. Gavina, L. Pulze, I. Giardino, M. Pettoello-Mantovani,
F. Omura, G. Osawa, K. Shewry, J. R. James, H. Sato, G. M. Bohr,
F. Omura, G. Osawa, K. Shewry, J. R. James, H. Sato, G. M. Bohr,
C. Settembre, M. Gavina, L. Pulze, I. Giardino, M. Pettoello-Mantovani,
V. E. Khot, A. Chargui, R. Belfidi, E. Corcelle, C. Duranton, I. Rubera,
S. L’Hoste, A. Chargui, R. Belfidi, C. Durand, I. Rubera, C. Poujol,
M. G. D. Rosen, J. B. Flower, M. J. Pitzikas, M. A. Carew, S. J. Dowling,
I. G. MacRae, A. I. Oates, L. Y. Yu, D. L. Prior, M. T. Stone, C. A. Friend,
E. Masliah, C. Cambon, and A. R. Johnson, Oxidative stress and
effects prove that mitochondrial DNA repair is inversely correlated with
D. Tsuda, T. Matsuda, M. Araki, J. Yamauchi, S. S. Taylor, M. Nakamura,
C. Marcinkowski, H. Murayama, M. R. D. Hunt, D. J. Martin, J. A. Rock, D.
L. Suchowerska, M. V., M. Barbet, G. D. P. Carvalho, J. de Carvalho,
Y. Zhang, X. Li, H. Grassme, G. Doring, E. Ulbinski, Alterations in ceramide
infection in cultured mice proximal tubules, American Journal of Physiology—R-
enzetti, W. Thiery, J. Thiery, M. Levec, M. Triantafyllou, G. A. Torchiano,
M. D’Apollito, I. Guiducci, A. R. Johnson, M. J. Pitzikas, M. A. Carew,
J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis,
M. Garcia, J. H. Williams, R. L. Cobb, J. A. Gallegos, C. J. Lin, T. Zhou, K.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntemi is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntem is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntemi is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntemi is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntem is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntem is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntem is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
A. J. Varady, A. J. yöntem is the new born associated
complex I in mammalian cells, Journal of Bioenergetics and Biomembranes
M. M. J. Pitzikas, M. A. Carew, S. J. Dowling, J. A. Rock, D. L. Prior, M.
G. Derosa, P. Maffioli, Peroxisome proliferator-activated receptor-gamma
subunit of complex I, Journal of Molecular Biology 319 (2002) 1211–1217.
aging and age-related macular degeneration, Experimental Eye Research 76 (2003) 397–403.

[204] B. van Houten, V. Woschner, J.H. Santos, Role of mitochondrial DNA in toxic responses to oxidative stress, DNA Repair (Amst) 5 (2006) 145–152.

[205] G. Escamis, L.C. Lin, K.A. García, L. García, J. García-Castrovejo, Mitochondrial DNA and inflammatory diseases, Human Genetics 131 (2012) 161–173.

[206] A.S. Patel, D. Morse, A.M. Chen. Regulation and functional significance of apoptosis in respiratory cell biology and disease, American Journal of Respiratory Cell and Molecular Biology 48 (1) (2012) 1–9.

[207] K.A. Markossian, B.S. Kuragov, Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes, Biochemistry (Mosk) 69 (2004) 971–984.

[208] A. Luciani, V.R. Villella, S. Esposito, N. Brunetti-Pierri, D.L. Medina, A.B. Fisher, C. Dodia, Y. Manevich, J.W. Chen, S.I. Feinstein, Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase, Autophagy 7 (2011) 1359–1370.

[209] A.O. Amer, Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis, Autophagy 7 (2011) 1359–1370.

[210] A. Luciani, V.R. Villella, S. Esposito, M. Gavina, I. Fruhwald, Y. Manevich, J. Fritsch, C. Eden, A.W. Smith, Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products, Infection and Immunity 65 (1997) 617–622.

[211] L.G. Gao, K.J. Kim, J.R. Yankaskas, H.J. Forman, Abnormal glutathione transport in cystic fibrosis airway epithelia, American Journal of Physiology 277 (1999) L113–118.

[212] P. Lindelli, J.W. Panahian, Glutathione permeability of CFTR, American Journal of Physiology Lung Cellular and Molecular Physiology 281 (2001) C323–326.

[213] L.W. Velsor, A. Van Heeckeren, B.J. Day, Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice, American Journal of Physiology Lung Cellular and Molecular Physiology 281 (2001) 131–38.

[214] J.C. Fernandez-Checa, C. Garcia-Ruiz, M. Ooikehns, N. Kaplowitz, Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats, Toxicon Kinetic studies in vitro and in vivo and susceptibility to oxidant stress, Journal of Clinical Investigation 87 (1991) 397–405.

[215] J. Martensson, A. Jain, W. Frager, A. Meister, Glutathione metabolism in the lung: inhibition of its synthesis leads to lamellar body and mitochondrial defects, Proceedings of the National Academy of Sciences of the United States of America 86 (1989) 5296–5300.

[216] J. Martensson, A. Meister, Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monooester, Proceedings of the National Academy of Sciences of the United States of America 86 (1989) 471–475.

[217] S. Trudel, M. Kelly, J. Fritsch, T. Nguyen-Khoa, P. Therond, M. Couturier, J. Martensson, A. Jain, W. Frager, A. Meister, Glutathione metabolism in the lung: modulation by oxidative stress and implications, Endocrine, Metabolic and Immune Disorders Drug Targets 11 (2011) 1–22.

[218] P. Linsdell, J.W. Hanrahan, Glutathione permeability of CFTR, American Journal of Physiology Lung Cellular and Molecular Physiology 281 (2001) C810–824.

[219] A. Meissner, J. Yang, J.T. Kroetsch, M. Sauve, H. Dax, M. Momen, M.H. Noyan-Ashraf, S. Hoxier, M. Husain, D. Lidington, S.S. Bolz, Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure, Circulation 122 (2012) 2739–2750.

[220] H. Nakamura, K. Yoshimura, G. Bajocchi, B.C. Trapnell, A. Pavirani, R.G. Crystal, Tumor necrosis factor modulator of expression of the cystic
fibrosis transmembrane conductance regulator gene, FEBBS Letters 314 (1992) 366–370.

[254] J.S. Elborn, D. Norman, F.M. Delamer, D.J. Shale, In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis, American Journal of Respiratory and Critical Care Medicine 147 (1993) 207–211.

[255] M.A. Brown, W.J. Morgan, P.R. Finley, P. Scuderi, Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis, Pediatric Pulmonology 10 (1991) 86–91.

[256] N. Vlij, S. Mazuur, P.L. Zeitlin, CFTR is a negative regulator of NFκB-mediated innate immune response, PLoS One 4 (2009) e4664.

[257] M.J. Lopez-Armada, B. Carames, M.A. Martin, B. Cillero-Pastor, M. Lires-Iglesias, N. Vij, S. Mazuur, P.L. Zeitlin, CFTR is a negative regulator of NFκB-mediated innate immune response, PLoS One 4 (2009) e4664.

[258] M. Clauzure, A.G. Valdivieso, T.A. Santa-Coloma / Redox Biology 1 (2013) 190–202

[259] M.S. Gelman, E.S. Kannegaard, R.R. Kopito, A principal role for the proteasome in autophagy, Current Biology 22 (2012) 73–82.

[260] A.J. Choi, S.W. Ryter, Autophagy in inflammatory diseases, International Journal of Molecular Science 13 (2012) 2132–2134.

[261] A. Tao, A. Sharma, R. Jen, A.F. Hirschfeld, M.A. Chilvers, P.M. Lavoie, E.W. Alton, P.K. Jeffery, A. Bush, J.C. Davies, Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis, Thorax 67 (2012) 167–172.

[262] H. Everett, G. McFadden, Apoptosis: an innate immune response to virus infection, Trends in Microbiology 7 (1999) 160–165.

[263] S.M. McWhirter, B.R. Tenoever, T. Maniatis, Connecting mitochondria and innate immunity, Cell 122 (2005) 645–647.

[264] R.B. Seth, L. Sun, Z.J. Chen, Antiviral innate immunity pathways, Cell Research 16 (2006) 141–147.

[265] I. Scott, Mitochondrial factors in the regulation of innate immunity, Mucosal and Infection 11 (2009) 729–736.

[266] V. Temkini, M. Karin, From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 Odyssey, Immunological Reviews 220 (2007) 8–21.

[267] A. Rudiger, M. Stutz, M. Singer, Cellular processes in sepsis, Swiss Medical Weekly 138 (2008) 629–634.

[268] G. Yeretsian, K. Labbe, M. Saleh, Regulation of mitochondrial inflammation and cell death, Cytoxic 43 (2008) 380–390.

[269] J.P. Ting, J.A. Duncan, Y. Bai, The cofilinfilamin-NLRS function in the innate immune system, Science 327 (2010) 286–290.

[270] D. Arnoult, L. Carneiro, I. Tattoli, S.E. Girardin, The role of mitochondria in cellular defense against microbial infection, Seminars in Immunology 21 (2009) 223–232.

[271] M. Delgado, S. Singh, S. Haro, S. Master, M. Ponpuak, C. Dinkins, W. ornatowski, I. Vergeve, V. Deretic, Autophagy and pattern recognition receptors in innate immunity, Immunological Reviews 227 (2009) 189–202.

[272] M.C. Tal, A. Iwasaki, Autophagic control of RLR signaling, Autophagy 5 (2009) 749–750.

[273] V. Deretic, Autophagy of intracellular microbes and mitochondria: two sides of the same coin? F1000 Biology Reports 2 (2010) 45.

[274] C. Kohchi, H. Inagawa, T. Nishizawa, G. Soma, ROS and innate immunity, Anticancer Research 29 (2009) 817–821.

[275] T. Finkel, Signal transduction by mitochondrial antioxidants, Journal of Biological Chemistry 287 (2012) 4434–4440.

[276] A.A. Manfredi, P. Rovere-Querinii, The mitochondrion—a Trojan horse that kicks off inflammation? New England Journal of Medicine 362 (2010) 2132–2134.

[277] D. Arnoult, F. Soares, I. Tattoli, S.E. Girardin, Mitochondria in innate immunity, EMBO Reports 12 (2011) 901–910.

[278] A.P. West, G.S. Shadel, S. Ghosh, Mitochondria in innate immune responses, Nature Reviews Immunology 11 (2011) 389–402.

[279] J.L. Liard, Innate immunity and mitochondrial disease: a complex affects the growth and intracellular survival of bacteria, Internation Journal of Medical Microbiology 201 (2009) 24–31.

[280] S.M. McWhirter, B.R. Tenoever, T. Maniatis, Connecting mitochondria and the innate immune system, Science 327 (2010) 286–290.

[281] J.P. Ting, J.A. Duncan, Y. Bai, The cofilinfilamin-NLRS function in the innate immune system, Science 327 (2010) 286–290.

[282] V. Deretic, Autophagy of intracellular microbes and mitochondria: two sides of the same coin? F1000 Biology Reports 2 (2010) 45.

[283] I. Scott, Mitochondrial factors in the regulation of innate immunity, Mucosal and Infection 11 (2009) 729–736.

[284] M.S. Gelman, E.S. Kannegaard, R.R. Kopito, A principal role for the proteasome in autophagy, Current Biology 22 (2012) 73–82.

[285] M.S. Cohen, A.M. Choi, Mitochondria: commanders of innate immunity and disease? Current Opinion in Immunology 24 (2012) 32–40.

[286] D. Arnoult, L. Galuzzi, G. Kroemer, Mitochondrial control of the NLRP3 inflammasome, Nature Immunology 11 (2012) 199–200.

[287] J. Tschopp, Mitochondria: sovereign of inflammation? European Journal of Immunology 41 (2011) 1196–1202.

[288] R. Zhou, A.S. Yazdi, P. Menu, J. Tschopp, A role for mitochondria in NLRP3 inflammasome activation, Nature 469 (2011) 221–225.

[289] M.S. Gelman, E.S. Kannegaard, R.R. Kopito, A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator, Journal of Biological Chemistry 277 (2002) 11709–11714.

[290] R.J. Devenish, Autophagy and the evasion of host defense: a new variation on the theme for Burkholderia cepacia? Autophagy 7 (2011) 1269–1270.

[291] A.J. Chao, S.W. Ryter, Involvement of inflammatory diseases, International Journal of Cell Biology 2011 (2011) ID 732798.

[292] J.A. Haspel, A.M. Choi, Autophagy: a core cellular process with emerging links to pulmonary disease, American Journal of Respiratory and Critical Medicine 186 (2012) 2132–2134.

[293] S.W. Ryter, K. Nakahira, J.A. Haspel, A.M. Choi, Autophagy in pulmonary diseases, Annual Review of Physiology 74 (2012) 377–401.

[294] M.A. Gavrilin, D.H. Abdelaziz, M. Mostafa, B.A. Abdulrahman, J. Grandhi, A. Akhtar, A. Abu Khweek, D.F. Aubert, M.A. Valvano, M.D. Wevers, A.O. Amer, Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia, Journal of Immunology 188 (2012) 3469–3477.

[295] A. Tang, A. Sharma, R. Jen, A.F. Hirnschlag, M.A. Chilvers, P.M. Lavoe, S.E. Surfey, Infarction and inflammation, boughts 8-16b reduction in humans with cystic fibrosis, PLoS One 7 (2012) e37689.